The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America - PubMed (original) (raw)
. 2008 Jan 15;46(2):155-64.
doi: 10.1086/524891.
Affiliations
- PMID: 18171244
- DOI: 10.1086/524891
The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America
Brad Spellberg et al. Clin Infect Dis. 2008.
Abstract
The ongoing explosion of antibiotic-resistant infections continues to plague global and US health care. Meanwhile, an equally alarming decline has occurred in the research and development of new antibiotics to deal with the threat. In response to this microbial "perfect storm," in 2001, the federal Interagency Task Force on Antimicrobial Resistance released the "Action Plan to Combat Antimicrobial Resistance; Part 1: Domestic" to strengthen the response in the United States. The Infectious Diseases Society of America (IDSA) followed in 2004 with its own report, "Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews," which proposed incentives to reinvigorate pharmaceutical investment in antibiotic research and development. The IDSA's subsequent lobbying efforts led to the introduction of promising legislation in the 109 th US Congress (January 2005-December 2006). Unfortunately, the legislation was not enacted. During the 110 th Congress, the IDSA has continued to work with congressional leaders on promising legislation to address antibiotic-resistant infection. Nevertheless, despite intensive public relations and lobbying efforts, it remains unclear whether sufficiently robust legislation will be enacted. In the meantime, microbes continue to become more resistant, the antibiotic pipeline continues to diminish, and the majority of the public remains unaware of this critical situation. The result of insufficient federal funding; insufficient surveillance, prevention, and control; insufficient research and development activities; misguided regulation of antibiotics in agriculture and, in particular, for food animals; and insufficient overall coordination of US (and international) efforts could mean a literal return to the preantibiotic era for many types of infections. If we are to address the antimicrobial resistance crisis, a concerted, grassroots effort led by the medical community will be required.
Comment in
- Why did it take the Infectious Diseases Society of America so long to address the problem of antibiotic resistance?
Kunin CM. Kunin CM. Clin Infect Dis. 2008 Jun 1;46(11):1791-2; author reply 1792-3; discussion 1793-4. doi: 10.1086/588057. Clin Infect Dis. 2008. PMID: 18462117 No abstract available.
Similar articles
- Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.
Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Talbot GH, et al. Clin Infect Dis. 2006 Mar 1;42(5):657-68. doi: 10.1086/499819. Epub 2005 Jan 25. Clin Infect Dis. 2006. PMID: 16447111 Review. - Why did it take the Infectious Diseases Society of America so long to address the problem of antibiotic resistance?
Kunin CM. Kunin CM. Clin Infect Dis. 2008 Jun 1;46(11):1791-2; author reply 1792-3; discussion 1793-4. doi: 10.1086/588057. Clin Infect Dis. 2008. PMID: 18462117 No abstract available. - Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
Spellberg B, Miller LG, Kuo MN, Bradley J, Scheld WM, Edwards JE Jr. Spellberg B, et al. Infection. 2007 Jun;35(3):167-74. doi: 10.1007/s15010-007-6269-7. Infection. 2007. PMID: 17565458 - Antimicrobial resistance: international control strategies, with a focus on limited-resource settings.
Diazgranados CA, Cardo DM, McGowan JE Jr. Diazgranados CA, et al. Int J Antimicrob Agents. 2008 Jul;32(1):1-9. doi: 10.1016/j.ijantimicag.2008.03.002. Int J Antimicrob Agents. 2008. PMID: 18550343 Review.
Cited by
- Targeting plasmid-encoded proteins that contain immunoglobulin-like domains to combat antimicrobial resistance.
Prieto A, Miró L, Margolles Y, Bernabeu M, Salguero D, Merino S, Tomas J, Corbera JA, Perez-Bosque A, Huttener M, Fernández LÁ, Juarez A. Prieto A, et al. Elife. 2024 Jul 24;13:RP95328. doi: 10.7554/eLife.95328. Elife. 2024. PMID: 39046772 Free PMC article. - New antibiotic agents in the pipeline and how they can help overcome microbial resistance.
Gould IM, Bal AM. Gould IM, et al. Virulence. 2013 Feb 15;4(2):185-91. doi: 10.4161/viru.22507. Epub 2013 Jan 9. Virulence. 2013. PMID: 23302792 Free PMC article. Review. - Novel antibacterial targets and compounds revealed by a high-throughput cell wall reporter assay.
Nayar AS, Dougherty TJ, Ferguson KE, Granger BA, McWilliams L, Stacey C, Leach LJ, Narita S, Tokuda H, Miller AA, Brown DG, McLeod SM. Nayar AS, et al. J Bacteriol. 2015 May;197(10):1726-34. doi: 10.1128/JB.02552-14. Epub 2015 Mar 2. J Bacteriol. 2015. PMID: 25733621 Free PMC article. - inPhocus: Perspectives of the Application of Bacteriophages in Poultry and Aquaculture Industries Based on Varms in China.
Zhao X, Zhang Q, Sicheritz-Pontén T, Liu Y, Clokie MRJ. Zhao X, et al. Phage (New Rochelle). 2021 Jun 1;2(2):69-74. doi: 10.1089/phage.2021.29016.xzh. Epub 2021 Jun 16. Phage (New Rochelle). 2021. PMID: 36148039 Free PMC article. No abstract available. - Promising new assays and technologies for the diagnosis and management of infectious diseases.
Mitsuma SF, Mansour MK, Dekker JP, Kim J, Rahman MZ, Tweed-Kent A, Schuetz P. Mitsuma SF, et al. Clin Infect Dis. 2013 Apr;56(7):996-1002. doi: 10.1093/cid/cis1014. Epub 2012 Dec 7. Clin Infect Dis. 2013. PMID: 23223587 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous